Tango Therapeutics, Inc. (TNGX) Stock Forecast
TNGX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 12 analysts
- Price target
- $44.88 average of analyst targets
- Upside to target
- +103.6% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.34
- 52-week range
- $7.50 – $32.90
TNGX analyst ratings
12 analystsNumber of analysts at each rating.
TNGX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TNGX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.42 | −$0.30 | $0.13 | −369.4% | 13 |
| Current fiscal year (2026) | −$1.40 | −$1.57 | −$1.17 | −$0.87 | −60.6% | 13 |
| Next fiscal year (2027) | −$1.66 | −$2.23 | −$1.24 | −$1.40 | −18.9% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TNGX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | −100.0% | 12 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 12 |
| Next fiscal year (2027) | $2.6M | $0 | $31.4M | 0.0% | 12 |
TNGX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TNGX revenue: reported and forecast
TNGX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.33 | −$0.35 | −$0.35 | −$0.35 | −$0.35 | +6.1% | 1 up · 2 down |
| Current fiscal year (2026) | −$1.29 | −$1.38 | −$1.40 | −$1.40 | −$1.40 | +8.0% | 0 up · 3 down |
| Next fiscal year (2027) | −$1.52 | −$1.64 | −$1.69 | −$1.69 | −$1.66 | +9.2% | 3 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TNGX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TNGX beat in 6 of 12.
What analysts expect from TNGX
12 analysts cover Tango Therapeutics; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $44.88, 103.6% above the latest close of $22.04. Analysts expect earnings of −$1.40 per share for 2026, −60.6% from a year earlier. For 2027 the average estimate is −$1.66 per share on revenue of $2.6 million. Tango Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: TNGX income statement, TNGX key metrics, TNGX chart. See the TNGX stock overview for the latest quote and news.
TNGX forecast FAQ
What is Tango Therapeutics's price target?
The average analyst price target for Tango Therapeutics is $44.88, 103.6% above the latest close of $22.04.
Is Tango Therapeutics a buy, hold or sell?
Of 12 analysts covering Tango Therapeutics, 10 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Tango Therapeutics's EPS forecast?
Analysts forecast −$1.40 per share for 2026 (range −$1.57 to −$1.17); for 2027 the estimate is −$1.66.
When does Tango Therapeutics report earnings?
Tango Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $-0.34.
Does Tango Therapeutics usually beat earnings estimates?
Tango Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.